Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Revenue (ASC 606) of $13.11 million for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $13.11M | +29.8% |
| 2024 | $10.09M | +29.9% |
| 2023 | $7.77M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.29M | +16.6% | +64.7% |
| June 30, 2025 | $2.00M | -9.5% | -17.7% |
| March 31, 2025 | $2.43M | -2.1% | -13.9% |
| September 30, 2024 | $2.82M | -29.3% | +27.8% |
| June 30, 2024 | $2.21M | — | -11.0% |
| March 31, 2024 | $2.48M | — | -37.8% |
| September 30, 2023 | $3.99M | — | — |
- Tonix Pharmaceuticals Holding Corp. showed an increase of +29.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Tonix Pharmaceuticals Holding Corp.’s revenue (asc 606) has grown by 68.7% (from $7.77 million to $13.11 million).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: